No recent analyst price targets found for IO.
Latest News for IO
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
AstraZeneca's IMFINZIÂ (durvalumab) in combination with Bacillus Calmette-GuÃrin (BCG) induction and maintenance therapy has been approved in the US for the
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IO.
U.S. House Trading
No House trades found for IO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.